{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:17:08Z","timestamp":1793110628340,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.euroneuro.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T08:38:02Z","timestamp":1549960682000},"page":"457-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review"],"prefix":"10.1016","volume":"29","author":[{"given":"Isabella","family":"Pacchiarotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-6798","authenticated-orcid":false,"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios D.","family":"Kotzalidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Verdolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-4420","authenticated-orcid":false,"given":"Andrea","family":"Murru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Goikolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Valent\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0986-8773","authenticated-orcid":false,"given":"Alberto","family":"Aedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.euroneuro.2019.02.003_bib0001","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0447.1981.tb00778.x","article-title":"Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium","volume":"64","author":"Ahlfors","year":"1981","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.euroneuro.2019.02.003_bib0002","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/08039488.2017.1411524","article-title":"Case series of diagnostic shift from bipolar disorder to schizoaffective disorder","volume":"72","author":"Argolo","year":"2018","journal-title":"Nord. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2019.02.003_bib0003","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WNF.0b013e318237709a","article-title":"A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder","volume":"34","author":"Bobo","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0004","first-page":"3111","article-title":"Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses","volume":"11","author":"Bortolato","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.euroneuro.2019.02.003_bib0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4088\/JCP.16m11201","article-title":"Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study","volume":"78","author":"Calabrese","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0006","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jad.2016.08.023","article-title":"Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: a 1-year retrospective cohort study","volume":"205","author":"Chan","year":"2016","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.euroneuro.2019.02.003_bib0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1601-5215.2010.00458.x","article-title":"A Pilot, 15-month, randomised effectiveness trial of Risperidone long acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder","volume":"22","author":"Chengappa","year":"2010","journal-title":"Acta Neuropsychiatr."},{"issue":"8","key":"10.1016\/j.euroneuro.2019.02.003_bib0008","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4088\/JCP.v61n0802","article-title":"Clinical factors associated with treatment noncompliance in euthymic bipolar patients","volume":"61","author":"Colom","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"suppl 3","key":"10.1016\/j.euroneuro.2019.02.003_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/NDT.S171002","article-title":"Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life","volume":"14","author":"Cuomo","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-244X-7-40","article-title":"Atypical antipsychotics in bipolar disorder: systematic review of randomised trials","volume":"7","author":"Derry","year":"2007","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0012","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1192\/bjp.148.6.723","article-title":"Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients","volume":"148","author":"Esparon","year":"1986","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2019.02.003_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.14m09416","article-title":"Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder","volume":"76","author":"Fu","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2019.02.003_bib0014","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/phar.1313","article-title":"Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review","volume":"33","author":"Gentile","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.euroneuro.2019.02.003_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/11631310-000000000-00000","article-title":"Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder","volume":"26","author":"Gigante","year":"2012","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.euroneuro.2019.02.003_bib0016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0269881109102919","article-title":"Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology","volume":"23","author":"Goodwin","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0017","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0018","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2012 on the long-term treatment of bipolar disorder","volume":"14","author":"Grunze","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2019.02.003_bib0019","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.euroneuro.2014.06.015","article-title":"Checking the plausibility of psychiatrists\u05f3 arguments for not prescribing depot medication","volume":"24","author":"Hamann","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.euroneuro.2019.02.003_bib0020","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.euroneuro.2012.04.014","article-title":"Patients' acceptance of the deltoid application of risperidone long-acting injection","volume":"22","author":"Heres","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0021","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0022","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jad.2017.04.074","article-title":"Bipolar patients treated with long-acting injectable risperidone in Taiwan: a 1-year mirror-image study using a national claims database","volume":"218","author":"Hsieh","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0024","first-page":"g5673","article-title":"Assessment and management of bipolar disorder: summary of updated NICE guidance","volume":"349","author":"Kendall","year":"2014","journal-title":"B.M.J."},{"issue":"9","key":"10.1016\/j.euroneuro.2019.02.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw038","article-title":"Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials","volume":"19","author":"Kishi","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl. 322","key":"10.1016\/j.euroneuro.2019.02.003_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0447.1985.tb08538.x","article-title":"Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients","volume":"72","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.euroneuro.2019.02.003_bib0027","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamapsychiatry.2017.4711","article-title":"Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder","volume":"75","author":"L\u00e4hteenvuo","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2019.02.003_bib0028","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.euroneuro.2006.08.004","article-title":"Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder","volume":"17","author":"Lindenmayer","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0029","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/1471-244X-13-340","article-title":"Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness","volume":"13","author":"Llorca","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2019.02.003_bib0030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1399-5618.2009.00761.x","article-title":"A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently","volume":"11","author":"Macfadden","year":"2009","journal-title":"Bipolar Disord."},{"issue":"7","key":"10.1016\/j.euroneuro.2019.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4088\/JCP.08m04408","article-title":"Treatment nonadherence and neurocognitive impairment in bipolar disorder","volume":"70","author":"Martinez-Aran","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1 Suppl.","key":"10.1016\/j.euroneuro.2019.02.003_bib0032","first-page":"24S","article-title":"Depot neuroleptics: side effects and safety","volume":"6","author":"Marder","year":"1986","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0033","series-title":"PICO Worksheet and Search Strategy National Center for Dental Hygiene Research","author":"Miller","year":"2001"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.euroneuro.2019.02.003_bib0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2012.01837.x","article-title":"Rates and clinical correlates of treatment non-adherence in schizoaffective bipolar patients","volume":"125","author":"Murru","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0036","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jad.2013.08.026","article-title":"Treatment adherence in bipolar I and schizoaffective disorder, bipolar type","volume":"151","author":"Murru","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.euroneuro.2019.02.003_bib0037","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bdi.12366","article-title":"Diagnostic reliability in schizoaffective disorder","volume":"18","author":"Murru","year":"2016","journal-title":"Bipolar Disord"},{"issue":"8","key":"10.1016\/j.euroneuro.2019.02.003_bib0038","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.euroneuro.2017.06.003","article-title":"A study on the bioequivalence of lithium and valproate salivary and blood levels in the treatment of bipolar disorder","volume":"27","author":"Murru","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0039","series-title":"Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care","year":"2018"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0040","series-title":"NHMRC Levels of Evidence and Grades For Recommendations for Developers of Guidelines","year":"2009"},{"issue":"1","key":"10.1016\/j.euroneuro.2019.02.003_bib0041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000314307","article-title":"Lithium: still a cornerstone in the long-term treatment in bipolar disorder?","volume":"62","author":"Nivoli","year":"2010","journal-title":"Neuropsychobiology"},{"issue":"3","key":"10.1016\/j.euroneuro.2019.02.003_bib0042","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4088\/JCP.09m05514yel","article-title":"Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study","volume":"71","author":"Perlis","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2019.02.003_bib0043","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1185\/03007990903488670","article-title":"Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries","volume":"26","author":"Peuskens","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.euroneuro.2019.02.003_bib0044","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euroneuro.2011.09.008","article-title":"Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder","volume":"22","author":"Popovic","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2019.02.003_bib0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","article-title":"Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder","volume":"68","author":"Quiroz","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0046","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/08039488.2013.801078","article-title":"What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?","volume":"68","author":"Samalin","year":"2014","journal-title":"Nord. J. Psychiatry"},{"issue":"May 3","key":"10.1016\/j.euroneuro.2019.02.003_bib0047","article-title":"Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables","author":"Sanchez-Moreno","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.euroneuro.2019.02.003_bib0048","first-page":"11","volume":"28","author":"Sa\u011flam Aykut","year":"2017","journal-title":"T\u00fcrk. Psikiyatri Derg."},{"issue":"5","key":"10.1016\/j.euroneuro.2019.02.003_bib0049","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.jcp.0000231609.91144.00","article-title":"Use of long-acting risperidone in the treatment of bipolar patients","volume":"26","author":"Savas","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0050","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"B.M.J."},{"issue":"6","key":"10.1016\/j.euroneuro.2019.02.003_bib0051","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/acps.12871","article-title":"Heterogeneity of functional outcomes in patients with bipolar disorder: a cluster-analytic approach","volume":"137","author":"Sol\u00e9","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.euroneuro.2019.02.003_bib0052","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/acps.12202","article-title":"Medication adherence in a comparative effectiveness trial for bipolar disorder","volume":"129","author":"Sylvia","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"issue":"Suppl. 52","key":"10.1016\/j.euroneuro.2019.02.003_bib0053","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1192\/bjp.195.52.s13","article-title":"Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review","volume":"195","author":"Taylor","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2019.02.003_bib0054","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2019.02.003_bib0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/acps.12447","article-title":"Comparison of psychotic bipolar disorder, schizoaffective disorder, and schizophrenia: an international, multisite study","volume":"133","author":"Tondo","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.euroneuro.2019.02.003_bib0056","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15622970701530917","article-title":"A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone","volume":"9","author":"Vieta","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2019.02.003_bib0057","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.euroneuro.2012.03.004","article-title":"A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder","volume":"22","author":"Vieta","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0058","doi-asserted-by":"crossref","first-page":"18008","DOI":"10.1038\/nrdp.2018.8","article-title":"Bipolar disorders","volume":"4","author":"Vieta","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"Suppl. 434","key":"10.1016\/j.euroneuro.2019.02.003_bib0059","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0447.2007.01059.x","article-title":"A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder","volume":"116","author":"Yatham","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2019.02.003_bib0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19301609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19301609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:52:42Z","timestamp":1760377962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X19301609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0924977X19301609"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.02.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}